Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhixiong Lin

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Frontiers in Molecular Neuroscience|November 18, 2021
Glyoxalase 1 Confers Susceptibility to Schizophrenia: From Genetic Variants to Phenotypes of Neural FunctionJingwen Yin, Guoda Ma, Shucun Luo, et al.
Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.
Cancer Cell|May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Yunpeng Yang, Jianji Pan, Hui Wang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Cancer Letters|March 12, 2016
CGCG clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Ying Mao, Wenbin Ma, et al.
Cancer Letters|November 9, 2020
Clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Cancer Letters|December 3, 2025
Updated clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Frontiers in Molecular Neuroscience|November 18, 2021
Glyoxalase 1 Confers Susceptibility to Schizophrenia: From Genetic Variants to Phenotypes of Neural FunctionJingwen Yin, Guoda Ma, Shucun Luo, et al.
Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.
Cancer Cell|May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Yunpeng Yang, Jianji Pan, Hui Wang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Cancer Letters|March 12, 2016
CGCG clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Ying Mao, Wenbin Ma, et al.
Cancer Letters|November 9, 2020
Clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Cancer Letters|December 3, 2025
Updated clinical practice guidelines for the management of adult diffuse gliomasTao Jiang, Do-Hyun Nam, Zvi Ram, et al.
Pageof 17